Ozanimod for the treatment of relapsing remitting multiple sclerosis

@article{Rasche2018OzanimodFT,
  title={Ozanimod for the treatment of relapsing remitting multiple sclerosis},
  author={L. Rasche and F. Paul},
  journal={Expert Opinion on Pharmacotherapy},
  year={2018},
  volume={19},
  pages={2073 - 2086}
}
  • L. Rasche, F. Paul
  • Published 2018
  • Medicine
  • Expert Opinion on Pharmacotherapy
  • ABSTRACT Introduction: Ozanimod is a selective sphingosine 1-phosphate receptor 1 and 5 modulator under development by Celgene, for the treatment of relapsing remitting multiple sclerosis. Extensive clinical experience has become available for the related compound fingolimod, favoring the sphingosine 1-phosphate therapeutic concept. Off-target effects have been attributed to its low receptor specificity and have prompted the development of next generation sphingosine 1-phosphate receptor… CONTINUE READING
    9 Citations
    Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis.
    • 4
    Effects of Massage Therapy on Multiple Sclerosis: a Case Report
    • Amy Frost-Hunt
    • Medicine
    • International journal of therapeutic massage & bodywork
    • 2020
    • PDF
    New era of therapy for endocrine autoimmune disorders

    References

    SHOWING 1-10 OF 207 REFERENCES
    Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
    • 17
    An update on cladribine for relapsing-remitting multiple sclerosis
    • 11
    Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    • 1,792
    • PDF
    A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    • 2,061
    • PDF
    Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod.
    • 12
    Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs
    • Ron Milo
    • Medicine
    • Expert opinion on pharmacotherapy
    • 2015
    • 15